(Total Views: 470)
Posted On: 11/05/2018 9:00:49 AM
Post# of 30067
11.5.19
Amended & 2nd Amended
5. Amarantus agreed to pay $1,000,000 to PGI upon receipt of funds from a 3rd party
biopharmaceutical company with which the Company agreed to merge its Elto Pharma subsidiary into.
That company is preparing to conduct an IPO on the Hong Kong Stock Exchange or NYSE (the “Merger”);
a. The Merger must be entered into by December 15th, 2018, and closed by April 23, 2018;
b. Upon the Merger, a minimum of $6,000,000 of dedicated funds must be raised by April eltoprazine into P hase 2b clinical trials for Parkinson's levodopa-induced dyskinesia
6. PGI may terminate the Elto License for certain breaches, including failure to enter into themerger by December 15th, 2018, or to close the Merger by April 23, 2019.
https://www.otcmarkets.com/stock/AMBS/disclosure
Aloha
Amended & 2nd Amended
5. Amarantus agreed to pay $1,000,000 to PGI upon receipt of funds from a 3rd party
biopharmaceutical company with which the Company agreed to merge its Elto Pharma subsidiary into.
That company is preparing to conduct an IPO on the Hong Kong Stock Exchange or NYSE (the “Merger”);
a. The Merger must be entered into by December 15th, 2018, and closed by April 23, 2018;
b. Upon the Merger, a minimum of $6,000,000 of dedicated funds must be raised by April eltoprazine into P hase 2b clinical trials for Parkinson's levodopa-induced dyskinesia
6. PGI may terminate the Elto License for certain breaches, including failure to enter into themerger by December 15th, 2018, or to close the Merger by April 23, 2019.
https://www.otcmarkets.com/stock/AMBS/disclosure
Aloha
(3)
(0)
